Sarepta Therapeutics (SRPT) Operating Margin (2012 - 2026)

Sarepta Therapeutics' Operating Margin history runs 13 years deep, the most recent figure standing at 89.54% for Q1 2026.

• In Q1 2026, Operating Margin rose 31483.0% year-over-year to 89.54%; the TTM figure through Mar 2026 stood at 2.21% (up 502.0% YoY), while the FY2025 annual figure was 31.83%, down 4330.0% from the prior year.
• Operating Margin was 89.54% for Q1 2026 at Sarepta Therapeutics, up from 92.92% in the prior quarter.
• In the past five years, Operating Margin ranged from a high of 89.54% in Q1 2026 to a low of 600.09% in Q2 2023.
• Historically, Operating Margin has averaged 86.75% across 5 years, with a median of 25.89% in 2025.
• The sharpest annual moves came in 2023 and 2024: Operating Margin sank 50012 bps in 2023, then surged 59989 bps in 2024.
• A 5-year view of Operating Margin shows it stood at 63.15% in 2022, then surged by 108 bps to 5.31% in 2023, then soared by 362 bps to 24.56% in 2024, then sank by 478 bps to 92.92% in 2025, then soared by 196 bps to 89.54% in 2026.
• The last three Operating Margin figures came in at 89.54% (Q1 2026), 92.92% (Q4 2025), and 25.89% (Q3 2025), per Business Quant data.